Logo

European Research Consortium Receives $1.6M from EU to Develop Array-Based Sequencing Technology

Aug 26, 2005

NEW YORK, Aug. 26 (GenomeWeb News) - A consortium of European companies and research institutions has received $1.6 million in funding from the European Commission to develop an array-based sequencing-by-synthesis technology from Quiatech, the Uppsala, Sweden-based company said on Wednesday.

 

Quiatech, as the project coordinator, will be responsible for dispersing the funds, according to Torbjorn Pettersson, a company spokesperson.

 

Besides Quiatech, members of the consortium are Asper Biotech of Tartu, Estonia; Fermentas of Vilnius, Lithuania; the University of Frankfurt in Germany, Tartu University in Estonia, and Silex Microsystems of Järfälla, Sweden.

 

The aim of the two-year project, to commence at the end of August, is to develop an array platform with thousands of oligonucleotide features for sequencing by synthesis. In a second phase, for which they may involve additional partners, the members plan to commercialize the resulting technology.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.